Asian Spectator


The Times

.

Mangroves Documentary Premieres, Exploring How Cities and Wetlands Coexist

SHENZHEN, CHINA – Media OutReach Newswire – 17 November 2026 – Guangdong Radio and Television has unveiled Mangroves, a three-part ecological documentary filmed in 4K ultra-high de...

OPPOHack 2022 final round coming this weekend: assisting innovative ubiquitous solutions land

SHENZHEN, CHINA - Media OutReach - 19 October 2022 - OPPOHack 2022 finals will take place on October 22 and 23, pacific time. After two preliminary rounds of hackathons, 10 qualified projec...

Semaglutide 2.4 mg injection demonstrated significant weight l...

BAGSVÆRD, Denmark, Nov. 5, 2020 /PRNewswire-AsiaNet / -- Results of a phase 3a trial showed that investigational drug semaglutide 2.4 mg once-weekly subcutaneous as an adjunct to inten...

Aitrasound® Medical Group Announces Completion of a Pre-A Financing Round of Nearly 60 Million Hong Kong Dollars

Launching New Brand Aitrasound® and an AI Medical Imaging Product LineHONG KONG SAR - Media OutReach Newswire - 26 April 2024 - Recently, Aitrasound® Medical Group (Telefield Medic...

Fight to Reunite: How Wuhan tackled COVID-19

BEIJING, March 16, 2020 /PRNewswire-AsiaNet/ -- In central China's Wuhan, the epicenter of the coronavirus outbreak, new COVID-19 cases have dropped to a single digit, with just four reporte...

SHERMAN THEATRICAL ENTERTAINMENT SET TO RELEASE "THE ROBBIE SH...

LONDON, Jan. 12, 2022 /PRNewswire-AsiaNet/ -- Sherman Theatrical Entertainment Ltd. ( https://c212.net/c/link/?t=0&l=en&o=3407642-1&h=314128436&u=http%3A%2F%2Fwww.shermanthea...

TUMI Taps Rosario Dawson For Women's Brand Campaign

NEW YORK, July 17, 2018 /PRNewswire-AsiaNet/ -- TUMI announced today the release of a global campaign to coincide with the launches of TUMI's newest women's collections, Georgica and Mezzani...

METZ blue launches three AI televisions in Hong Kong

HONG KONG, Nov. 6, 2018 /PRNewswire-AsiaNet/ -- On November 6th, 2018, the high-end branch of SKYWORTH, METZ blue, successfully entered the Hong Kong market with a grand opening ceremony. Th...

JW Therapeutics Announces Initiation of Clinical Study of JWAT...

SHANGHAI, July 4, 2022 /PRNewswire-AsiaNet/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cel...

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

TOKYO, Jul 9, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Eisai's and Merck's applications seeking accelerated approval of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, Merck's anti-PD-1 therapy, for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).The applications were based on data from the Phase 1b Study 116/KEYNOTE-524 trial, which showed clinically meaningful efficacy in the single-arm setting. These data were recently presented at the 2020 American Society of Clinical Oncology Annual Meeting and supported a Breakthrough Therapy designation granted by the FDA in July 2019. Ahead of the PDUFA action dates of Eisai's and Merck's applications, another combination therapy was approved based on a randomized controlled trial that demonstrated overall survival. Consequently, the CRL stated that the applications do not provide evidence that KEYTRUDA in combination with LENVIMA represents a meaningful advantage over available therapies for the treatment of unresectable or metastatic HCC with no prior systemic therapy for advanced disease. Since the applications for Study 116/KEYNOTE-524 no longer meet the criteria for accelerated approval, both companies plan to work with the FDA to take appropriate next steps, which include conducting a well-controlled clinical trial that demonstrates substantial evidence of effectiveness and the clinical benefit of the combination. As such, LEAP-002, the Phase 3 trial evaluating the LENVIMA plus KEYTRUDA combination as a first-line treatment for advanced HCC, is currently underway and fully enrolled. The CRL does not impact the currently approved indications for LENVIMA or for KEYTRUDA.Eisai and Merck are continuing to evaluate the LENVIMA plus KEYTRUDA combination across 13 different tumor types in 18 clinical trials including the LEAP (LEnvatinib And Pembrolizumab) clinical program.

For more information, visit https://www.eisai.com/news/2020/news202039.html.

About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Contact:Eisai Co., Ltd.
Public Relations:
+81-(0)3-3817-5120
  
Merck & Co., Inc., Kenilworth, N.J., U.S.A. 
Media Relations
Pamela Eisele: (267) 305-3558
Michael Close: (267) 305-1211

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegaluk casinos not on gamstophttps://www.capitolcitycinema.org/grandpashabet girisStreamEastStreamEastjojobet